Nasdaq

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell ...

Treating previously untreatable cancers: How CAR‑T cell therapy could be made accessible to more patients

CAR-T cell therapies advance the treatment of cancer, but they are expensive and can take weeks to process. Academic ...
Nasdaq

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell ...